» Articles » PMID: 34760721

Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases

Overview
Date 2021 Nov 11
PMID 34760721
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Novel coronavirus SARS-CoV2 is evolving continuously with emergence of several variants of increasing transmission capabilities and pandemic potential. Generation of variants occurs through accumulation of mutations due to the RNA nature of viral genome, which is further enhanced by variable selection pressures of this ongoing pandemic. COVID-19 presentations of SARS-CoV2 are mainly pulmonary manifestations with or without mild gastrointestinal (GI) and hepatic symptoms. However, the virus has evolved beyond pulmonary manifestations to multisystem disorder due to systemic inflammation and cytokine storm. Definitive cause of acute or late onset of inflammation, infection in various organs, and host response to emerging variants lacks clarity and needs elucidation. Several studies have reported underlying diseases including diabetes, hypertension, obesity, cardio- and cerebrovascular disorders, and immunocompromised conditions as significant risk factors for severe form of COVID-19. Pre-existing liver and GI diseases are also highly predominant in the population, which can alter COVID-19 outcome due to altered immune status and host response. We aim to review the emerging variants of SARS-CoV2 and host response in patients with pre-existing liver and GI diseases.

Methods: In this review, we have elucidated the emergence and characteristic features of new SARS-CoV2 variants, mechanisms of infection and host immune response, GI and hepatic manifestation with radiologic features of COVID-19, and outcomes in pre-existing liver and GI diseases.

Key Findings: Emerging variants of concern (VOC) have shown increased transmissibility and virulence with severe COVID-19 presentation and mortality. There is a drastic swift of variants from the first wave to the next wave of infections with predominated major VOC including alpha (B.1.1.7, UK), beta (B.1.351, South Africa), gamma (B.1.1.28.1, Brazil), and delta (B1.1.617, India) variants. The mutations in the spike protein of VOC are implicated for increased receptor binding (N501Y, P681R) and immune escape (L452R, E484K/Q, T478K/R) to host response. Pre-existing liver and GI diseases not only have altered tissue expression and distribution of viral entry ACE2 receptor but also host protease TMPRSS2, which is required for both spike protein binding and cleavage to initiate infection. Altered immune status due to pre-existing conditions results in delayed virus clearance or prolonged viremia. Even though GI and hepatic manifestations of SARS-CoV2 are less severe, the detection of virus in patient's stool indicates GI tropism, replication, and shedding from the GI tract. COVID-19-induced liver injury, acute hepatic decompensation, and incidences of acute-on-chronic liver failure may change the disease outcomes.

Conclusions: The changes in the spike protein of emerging variants, immunomodulation by viral proteins, and altered expression of host viral entry receptor in pre-existing diseases are the key determinants of host response to SARS-CoV2 and its disease outcome.

Citing Articles

Clinical and Genomic Perspective of SARS CoV-2 Infection in Liver Disease Patients: A Single-Centre Retrospective Study.

Agarwal R, Bhugra A, Gautam P, Suroliya V, Chhabra R, Pandey A Curr Microbiol. 2024; 81(9):301.

PMID: 39115704 DOI: 10.1007/s00284-024-03786-7.


COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?.

Michalak A, Lach T, Szczygiel K, Cichoz-Lach H Int J Mol Sci. 2024; 25(4).

PMID: 38396888 PMC: 10888568. DOI: 10.3390/ijms25042212.


Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications.

Durairajan S, Singh A, Saravanan U, Namachivayam M, Radhakrishnan M, Huang J Viruses. 2023; 15(6).

PMID: 37376531 PMC: 10304713. DOI: 10.3390/v15061231.


SARS-CoV-2 evolution among patients with immunosuppression in a nosocomial cluster of a Japanese medical center during the Delta (AY.29 sublineage) surge.

Hosaka Y, Yan Y, Naito T, Oyama R, Tsuchiya K, Yamamoto N Front Microbiol. 2023; 14:944369.

PMID: 36846745 PMC: 9947280. DOI: 10.3389/fmicb.2023.944369.


Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program.

Silva J, de Lima A, Alvim L, Malta F, Mendonca C, Fonseca P Viruses. 2022; 14(5).

PMID: 35632589 PMC: 9143796. DOI: 10.3390/v14050847.


References
1.
Phelan A, Katz R, Gostin L . The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020; 323(8):709-710. DOI: 10.1001/jama.2020.1097. View

2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

3.
Nowak J, Lindstrom J, Kalla R, Ricanek P, Halfvarson J, Satsangi J . Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor and in Inflammatory Bowel Disease. Gastroenterology. 2020; 159(3):1151-1154.e2. PMC: 7217073. DOI: 10.1053/j.gastro.2020.05.030. View

4.
Manzia T, Gazia C, Lenci I, Angelico R, Toti L, Monaco A . Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor. Am J Transplant. 2021; 21(7):2600-2604. PMC: 8013325. DOI: 10.1111/ajt.16548. View

5.
Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M . The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS One. 2021; 16(2):e0246190. PMC: 7886178. DOI: 10.1371/journal.pone.0246190. View